tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR), Vir Biotechnology (VIR) and Akero Therapeutics (AKRO)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on United Therapeutics (UTHRResearch Report), Vir Biotechnology (VIRResearch Report) and Akero Therapeutics (AKROResearch Report).

United Therapeutics (UTHR)

In a report issued on July 15, Jessica Fye from J.P. Morgan maintained a Buy rating on United Therapeutics, with a price target of $248.00. The company’s shares closed last Friday at $240.08, close to its 52-week high of $245.48.

According to TipRanks.com, Fye is a 4-star analyst with an average return of 9.0% and a 53.8% success rate. Fye covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals, Intra-Cellular Therapies, and Emergent Biosolutions.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for United Therapeutics with a $255.33 average price target.

See today’s best-performing stocks on TipRanks >>

Vir Biotechnology (VIR)

J.P. Morgan analyst Christopher Neyor maintained a Hold rating on Vir Biotechnology on July 15 and set a price target of $35.00. The company’s shares closed last Friday at $29.02.

According to TipRanks.com, Neyor is ranked #5901 out of 7915 analysts.

Vir Biotechnology has an analyst consensus of Moderate Buy, with a price target consensus of $55.00.

Akero Therapeutics (AKRO)

In a report issued on July 15, Eric Joseph from J.P. Morgan maintained a Buy rating on Akero Therapeutics, with a price target of $30.00. The company’s shares closed last Friday at $11.04.

According to TipRanks.com, Joseph is a 3-star analyst with an average return of 0.9% and a 50.0% success rate. Joseph covers the Healthcare sector, focusing on stocks such as Recursion Pharmaceuticals, Rocket Pharmaceuticals, and Atea Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Akero Therapeutics with a $46.00 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on UTHR:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
---

Latest News Feed